News for Rhythm Pharmaceuticals, Inc. (RYTM)

On May 29, 2025, Stifel analyst Paul Matteis maintained a "Buy" rating for Rhythm Pharmaceuticals (RYTM) while raising the target price from USD 78.00 to USD 94

Stifel analyst Paul Matteis has increased the target price for Rhythm Pharmaceuticals (RYTM) to $94, up from the previous $78, while maintaining a Buy rating on

Rhythm Pharmaceuticals (RYTM) has revealed promising findings from new, real-world data highlighting the effects of setmelanotide on patients with hypothalamic

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ETCompany ParticipantsDavid Connolly - IRDavid Meeker -...

The following slide deck was published by Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals (RYTM) reported a first-quarter revenue of $32.704 million, falling short of analysts' projections of $40.16 million. The company remains

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -17.39% and 18.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

**media[617216]**

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM), a global commercial-stage biopharmaceutical company focused on transforming the

Significant Reduction in Holdings On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a notable reduction in its holdings of Rhythm Pharmaceuticals

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM), a global commercial-stage biopharmaceutical company focused on transforming t

- **Rhythm Pharmaceuticals (RYTM) sees a 17.1% surge as the Nasdaq Index rebounds.** - **Analysts predict a substantial 41.9% earnings growth this year for RYTM

U.S. stock markets are showing signs of recovery today after experiencing one of the most volatile trading sessions in recent history. As of the market close

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday. Shares of Marvell Technology, Inc. MRVL rose sharply during Tuesday's s...

Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Key Highlights: Rhythm Pharmaceuticals' setmelanotide shows promising results in Phase 3 trial for hypothalamic obesity. Analysts foresee a potential ups

**media[587682]**

Company to host conference call on April 7 at 8 a.m. ETBOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commer

Rhythm Pharmaceuticals Inc (RYTM), a Boston-based biopharmaceutical company, announced on March 20, 2025, that it has reacquired the rights to its drug IMCIVREE